|
||||||||||||||||||||||
|
|
Effect of Low Molecular Weight Heparin :Tinzaparin in Lung Tumours (TILT)
Basic Trial Information
Summary Experiments suggest that low molecular weight heparin (LMWH) inhibit tumor growth and metastasis. Studies in humans suggest that LMWH is associated with a higher survival in patients with cancer related thrombosis. Two recent studies suggest that LMWH may increase the survival of patients with cancer who do not have an associated thrombosis. The purpose of the study is to assess the effect of LMWH on the overall survival of patients with localized non small cell lung cancer after complete surgical resection. Further Study Information Phase III, prospective, multicentric, randomized, controlled, open, trial in parallel groups with a blind adjudication of all end-point criteria. Reference therapy : Patients randomized to the control group will receive postoperative treatment according to local practice in the participating centers. However, the participating centers will have to comply with the following guidelines.
Patients with a contraindication to postoperative chemotherapy and those who refuse chemotherapy can be included in the study provided they fulfill all inclusion and exclusion criteria. Experimental treatment Experimental treatment is tinzaparin administered subcutaneously once a day at the dose of 100 IU/Kg during a twelve week period beginning after a maximum period of 8 weeks after surgery. Patients randomized in the experimental group will receive adjuvant postoperative treatment according to local practice with the same guidelines as in the control group. Patients follow-up All patients will be followed according to local practice, but at least two outpatients visits with a chest radiograph will be planned each year during the five-year follow-up period. Duration of the trial. Inclusion period (first patient in to last patient in) : 3 years. Patient total follow-up (from surgery to end of follow-up) : 5 years. Total study period : 8 years. Eligibility Criteria Inclusion Criteria:
Exclusion Criteria:
Trial Lead Organizations/Sponsors Assistance Publique Hopitaux de Paris
Trial Sites
Link to the current ClinicalTrials.gov record. Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain
the same text. Minor
changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and
contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should
be directed to ClinicalTrials.gov. Back to Top |
NCI Home |
Images Version |
Contact Us |
Policies |
Accessibility |
Viewing Files |
FOIA |
Site Help |
Site Map
|
A Service of the National Cancer Institute |